id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5625-0015,FDA,FDA-2017-D-5625,Recommendations for Dual 510(k) and Clinical Laboratory Improvement Amendments Waiver by Application Studies; Guidance for Industry and Food and Drug Administration Staff; Availability,Notice,Notice of Data Availability,2020-02-26T05:00:00Z,2020,2,2020-02-26T05:00:00Z,,2020-02-26T15:03:25Z,2020-03859,0,0,09000064843b4ec8
FDA-2017-D-5625-0016,FDA,FDA-2017-D-5625,Recommendations for Dual 510(k) and CLIA Waiver by Application Studies Guidance for Industry and Food and Drug Administration Staff,Other,Guidance,2020-02-26T05:00:00Z,2020,2,2020-02-26T05:00:00Z,,2024-11-06T23:33:00Z,,1,0,09000064843b6329
FDA-2017-D-5625-0012,FDA,FDA-2017-D-5625,Draft Guidance for Industry and FDA_name_Recommendations for Dual 510(k) and CLIA Wavier by Application Studies_11-29-2018,Other,Guidance,2018-11-29T05:00:00Z,2018,11,2018-11-29T05:00:00Z,2019-02-28T04:59:59Z,2024-11-12T22:50:42Z,,1,0,090000648390cf30
FDA-2017-D-5625-0011,FDA,FDA-2017-D-5625,"Recommendations for Dual 510(k) and Clinical Laboratory Improvement
Amendments Waiver by Application Studies; Draft Guidance for Industry
and Food and Drug Administration Staff; Availability",Notice,Notice of Availability,2018-11-29T05:00:00Z,2018,11,2018-11-29T05:00:00Z,2019-02-28T04:59:59Z,2024-11-12T22:50:46Z,2018-25960,1,0,090000648390c0b9
FDA-2017-D-5625-0005,FDA,FDA-2017-D-5625,"Recommendations for Dual 510(k) and Clinical Laboratory Improvement
Amendments Waiver by Application Studies; Draft Guidance for Industry
and Food and Drug Administration Staff; Availability; Extension of  Comment Period",Notice,Notice of Availability,2018-01-26T05:00:00Z,2018,1,2018-01-26T05:00:00Z,2018-03-31T03:59:59Z,2018-03-31T01:00:39Z,2018-01350,0,0,0900006482e6c0cd
FDA-2017-D-5625-0004,FDA,FDA-2017-D-5625,"Request for Extension from Coalition for CLIA Waiver Reform (Epstein Becker & Green, P.C.)",Other,Electronic Regulation from Form,2018-01-08T05:00:00Z,2018,1,2018-01-08T05:00:00Z,,2018-01-08T16:23:20Z,,0,0,0900006482d9db46
FDA-2017-D-5625-0002,FDA,FDA-2017-D-5625,Recommendations for Dual 510(k) and CLIA Waiver by Application Studies Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE,Other,Guidance,2017-11-29T05:00:00Z,2017,11,2017-11-29T05:00:00Z,2018-03-31T03:59:59Z,2024-11-07T01:12:24Z,,1,0,0900006482cbce95
FDA-2017-D-5625-0001,FDA,FDA-2017-D-5625,"Recommendations for Dual 510(k) and Clinical Laboratory Improvement
Amendments Waiver by Application Studies; Draft Guidance for Industry
and Food and Drug Administration Staff; Availability",Notice,Notice of Availability,2017-11-29T05:00:00Z,2017,11,2017-11-29T05:00:00Z,2018-01-30T04:59:59Z,2018-01-14T03:27:10Z,2017-25774,0,0,0900006482cbbd24